RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aeglea Bio Therapeutics - Stock

Aeglea Bio Therapeutics P/S 2024

Aeglea Bio Therapeutics P/S

9.85

Ticker

AGLE

ISIN

US00773J1034

WKN

A2AG5H

As of Jun 29, 2024, Aeglea Bio Therapeutics's P/S ratio stood at 9.85, a 15.88% change from the 8.5 P/S ratio recorded in the previous year.

The Aeglea Bio Therapeutics P/S history

Aeglea Bio Therapeutics Aktienanalyse

What does Aeglea Bio Therapeutics do?

Aeglea Bio Therapeutics Inc is a biotechnology company that aims to develop innovative treatments for rare genetic diseases and cancer. The company was founded in 2013 in Austin, Texas, and is listed on the NASDAQ stock exchange since March 2017. Aeglea Bio Therapeutics specializes in the development and commercialization of therapeutics for rare genetic diseases and cancer. They have a pipeline of products in clinical development focusing on various indications, including arginemia, ASS1-negative cancer, and metastatic breast cancer. Their first therapeutic application, Pegzilarginase, was approved by the FDA in January 2021 for the treatment of arginemia. They also have other products in clinical development, such as AEB1102 for ASS1-negative cancer and AEB3103 for metastatic breast cancer. Aeglea Bio Therapeutics works with patient organizations to advance research and development of therapies and improve patient access to new treatment options. Overall, Aeglea Bio Therapeutics has the potential to become a significant player in the biotechnology industry. Aeglea Bio Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Aeglea Bio Therapeutics's P/S Ratio

Aeglea Bio Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Aeglea Bio Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Aeglea Bio Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Aeglea Bio Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Aeglea Bio Therapeutics Stock

What is the price-to-earnings ratio of Aeglea Bio Therapeutics?

The price-earnings ratio of Aeglea Bio Therapeutics is currently 9.85.

How has the price-earnings ratio of Aeglea Bio Therapeutics changed compared to last year?

The price-to-earnings ratio of Aeglea Bio Therapeutics has increased by 15.88% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Aeglea Bio Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Aeglea Bio Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Aeglea Bio Therapeutics affect the company?

An increase in the price-earnings ratio of Aeglea Bio Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Aeglea Bio Therapeutics affect the company?

A decrease in the price-earnings ratio of Aeglea Bio Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Aeglea Bio Therapeutics?

Some factors that influence the price-earnings ratio of Aeglea Bio Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Aeglea Bio Therapeutics pay?

Over the past 12 months, Aeglea Bio Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aeglea Bio Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aeglea Bio Therapeutics?

The current dividend yield of Aeglea Bio Therapeutics is .

When does Aeglea Bio Therapeutics pay dividends?

Aeglea Bio Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aeglea Bio Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aeglea Bio Therapeutics located?

Aeglea Bio Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aeglea Bio Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aeglea Bio Therapeutics from 6/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/29/2024.

When did Aeglea Bio Therapeutics pay the last dividend?

The last dividend was paid out on 6/29/2024.

What was the dividend of Aeglea Bio Therapeutics in the year 2023?

In the year 2023, Aeglea Bio Therapeutics distributed 0 USD as dividends.

In which currency does Aeglea Bio Therapeutics pay out the dividend?

The dividends of Aeglea Bio Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aeglea Bio Therapeutics

Our stock analysis for Aeglea Bio Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aeglea Bio Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.